Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 4Prostatic Neoplasms 3Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumour 1Recurrence 1Ovarian Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lung Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer) 1Healthy Participants 1Endometrial Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumours 1Advanced Solid Malignancy, 1Advanced Solid Malignancy 1Advanced Gastric Cancer 1Advanced Cancer 1Adenocarcinoma 1

Interventions

Everolimus 5Alpelisib 4berzosertib 3PX-866 3Letrozole 3Fulvestrant 3Cetuximab 3Topotecan 2NVP-BKM120 2tipifarnib 1sotorasib 1serabelisib 1ribociclib 1pembrolizumab 1parsaclisib 1palbociclib 1gedatolisib 1duvelisib 1ceralasertib 1capivasertib 1binimetinib 1Trimetazidine 1Paclitaxel 1Oxaliplatin 1Leuprolide 1Leucovorin 1Irinotecan 1Goserelin 1Fluorouracil 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hereditary Sensory and Autonomic Neuropathies × capivasertib × Clear all
NCT01226316 2025-06-29

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

AstraZeneca

Phase 1 Completed
285 enrolled
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡